Analysis of Claudin-1 and -4 as potential treatment targets in penile squamous cell carcinoma

Background Penile carcinoma (PC) is a rare malignancy with an adverse prognosis for patients with tumors at advanced stages. Platinum-based chemotherapy still represents the standard of care but offers limited long-term survival benefit, necessitating the exploration of additional therapeutic targets. Claudin-1 and Claudin-4, key components of cellular tight junctions, play a role in the evolution and progression of various tumor types and may play a therapeutic role in PC. Methods In this study, we analyzed the expression and prognostic value of Claudin-1 and Claudin-4 in a multi-institutional international cohort ( n = 193) of patients with PC. Tissue microarrays (TMAs) comprising representative tumor cores from the tumor center, invasive front, lymph node metastases, and normal penile tissue were used. H-scores of Claudin-1 and Claudin-4 were compared across tumor localizations, tumor stages, histologic subtypes, grades and HPV groups. Patient survival was correlated with Claudin-1 and Claudin-4 expression via Kaplan-Meier analysis. Results Claudin-1 was consistently expressed across tumor locations and was expressed in both HPV+ and HPV- tumors. Furthermore, Claudin-1 expression in FRONT samples was moderately correlated with its expression in CENTER samples. No significant differences in Claudin-1 expression were observed between different tumor stages, histologic subtypes and other clinicopathological characteristics. Moderate or strong Claudin-4 expression (H-score ≥ 100) was observed in 13.5% and 11.5% of FRONT and CENTER samples, respectively. The difference in OS between Claudin-4 CENTER expression groups was nominally significant ( p = 0.024) but not after correction for multiple testing (adjusted p = 0.21). Conclusion Claudin-1 and, to a lesser extent, Claudin-4 are expressed in PC and corresponding metastases, supporting further investigation of these proteins as candidate targets in local and advanced PC.

Authors

Institutions

Publication Details

Journal
Diagnostic Pathology
Published
2026-11-18
DOI
https://doi.org/10.1186/s13000-026-01874-9
Primary Topic
Genital Health and Disease
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Analysis of Claudin-1 and -4 as potential treatment targets in penile squamous cell carcinoma

August Fiegl, Kerstin Junker, Kristof Bende, Oybek Khalmurzaev et al.
Diagnostic Pathology
Genital Health and Disease
article

Analysis of Claudin-1 and -4 as potential treatment targets in penile squamous cell carcinoma

August Fiegl, Kerstin Junker, Kristof Bende, Oybek Khalmurzaev, Cármen Jerónimo, Rui Henrique, Vsevolod Matveev, Stefan Lohse, Joachim Steffens, João Lobo, Hagen Loertzer, Rainer Maria Bohle, Arndt Hartmann, Heiko Wunderlich, Carol Imanuel Geppert, Alexey Pryalukhin, Michael Stöckle, Jan Mink
article en

Abstract

Background Penile carcinoma (PC) is a rare malignancy with an adverse prognosis for patients with tumors at advanced stages. Platinum-based chemotherapy still represents the standard of care but offers limited long-term survival benefit, necessitating the exploration of additional therapeutic targets. Claudin-1 and Claudin-4, key components of cellular tight junctions, play a role in the evolution and progression of various tumor types and may play a therapeutic role in PC. Methods In this study, we analyzed the expression and prognostic value of Claudin-1 and Claudin-4 in a multi-institutional international cohort ( n = 193) of patients with PC. Tissue microarrays (TMAs) comprising representative tumor cores from the tumor center, invasive front, lymph node metastases, and normal penile tissue were used. H-scores of Claudin-1 and Claudin-4 were compared across tumor localizations, tumor stages, histologic subtypes, grades and HPV groups. Patient survival was correlated with Claudin-1 and Claudin-4 expression via Kaplan-Meier analysis. Results Claudin-1 was consistently expressed across tumor locations and was expressed in both HPV+ and HPV- tumors. Furthermore, Claudin-1 expression in FRONT samples was moderately correlated with its expression in CENTER samples. No significant differences in Claudin-1 expression were observed between different tumor stages, histologic subtypes and other clinicopathological characteristics. Moderate or strong Claudin-4 expression (H-score ≥ 100) was observed in 13.5% and 11.5% of FRONT and CENTER samples, respectively. The difference in OS between Claudin-4 CENTER expression groups was nominally significant ( p = 0.024) but not after correction for multiple testing (adjusted p = 0.21). Conclusion Claudin-1 and, to a lesser extent, Claudin-4 are expressed in PC and corresponding metastases, supporting further investigation of these proteins as candidate targets in local and advanced PC.

Diagnostic PathologyVol. 21(1)
Friedrich-Alexander-Universität Erlangen-Nürnberg (DE), Universitätsklinikum Erlangen (DE), Westpfalz Klinikum (DE), Universitätsklinikum des Saarlandes (DE), Instituto Português de Oncologia Francisco Gentil (PT), Sankt-Antonius-Hospital Eschweiler (DE), Ministry of Health of the Russian Federation (RU), Comprehensive Cancer Center Erlangen (DE), Universitätsklinikum Wiener Neustadt (AT), Saarland University (DE)
Universitätsklinikum Erlangen
Good health and well-being
Genital Health and Disease
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon